[
  {
    "ts": null,
    "headline": "Harbor Capital Factor U.S. Large Cap ETF Q4 2024 Commentary",
    "summary": "During the fourth quarter, Harbor Human Capital Factor US Large Cap ETF returned 2.72%, (at NAV) slightly underperforming CIBC Human Capital Index, which returned 2.80%.",
    "url": "https://finnhub.io/api/news?id=d513c95f6496914a3dbc2eb9f9d0b1f3e3ebba81993138c72ceab7f04b45ca60",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744283580,
      "headline": "Harbor Capital Factor U.S. Large Cap ETF Q4 2024 Commentary",
      "id": 133847889,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2170834274/image_2170834274.jpg?io=getty-c-w1536",
      "related": "UNH",
      "source": "SeekingAlpha",
      "summary": "During the fourth quarter, Harbor Human Capital Factor US Large Cap ETF returned 2.72%, (at NAV) slightly underperforming CIBC Human Capital Index, which returned 2.80%.",
      "url": "https://finnhub.io/api/news?id=d513c95f6496914a3dbc2eb9f9d0b1f3e3ebba81993138c72ceab7f04b45ca60"
    }
  },
  {
    "ts": null,
    "headline": "Macro Headwind-Immune CVS Health Stock Set to Extend 50% YTD Rally",
    "summary": "CVS Health (CVS) is a top S&P 500 performer in 2025, with year-to-date returns exceeding 50%. Moreover, the stock has shirked off Trump-mania, tariff levies, and a global trade war like water off a duck’s back. The stock is up 3% over the past five days and up 42% since January — wholly opposed to the market squall enveloping the world’s major stock indices and shaving trillions from index valuations, in recent days. Most recognizable for its corner drugstores, CVS’ transformative acquisition of",
    "url": "https://finnhub.io/api/news?id=feb8331bf21911144e9d57a3f16250c62833a9887c6ab8cec102d8d3f04ee5d3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744282187,
      "headline": "Macro Headwind-Immune CVS Health Stock Set to Extend 50% YTD Rally",
      "id": 133844031,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "UNH",
      "source": "Yahoo",
      "summary": "CVS Health (CVS) is a top S&P 500 performer in 2025, with year-to-date returns exceeding 50%. Moreover, the stock has shirked off Trump-mania, tariff levies, and a global trade war like water off a duck’s back. The stock is up 3% over the past five days and up 42% since January — wholly opposed to the market squall enveloping the world’s major stock indices and shaving trillions from index valuations, in recent days. Most recognizable for its corner drugstores, CVS’ transformative acquisition of",
      "url": "https://finnhub.io/api/news?id=feb8331bf21911144e9d57a3f16250c62833a9887c6ab8cec102d8d3f04ee5d3"
    }
  },
  {
    "ts": null,
    "headline": "Health Insurance Providers Stocks Q4 Teardown: Humana (NYSE:HUM) Vs The Rest",
    "summary": "Let’s dig into the relative performance of Humana (NYSE:HUM) and its peers as we unravel the now-completed Q4 health insurance providers earnings season.",
    "url": "https://finnhub.io/api/news?id=07abc5d04eff5236b7913345e78599b99167415cfa7ea4d063db7636ec2c06ac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744276120,
      "headline": "Health Insurance Providers Stocks Q4 Teardown: Humana (NYSE:HUM) Vs The Rest",
      "id": 133844033,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "UNH",
      "source": "Yahoo",
      "summary": "Let’s dig into the relative performance of Humana (NYSE:HUM) and its peers as we unravel the now-completed Q4 health insurance providers earnings season.",
      "url": "https://finnhub.io/api/news?id=07abc5d04eff5236b7913345e78599b99167415cfa7ea4d063db7636ec2c06ac"
    }
  },
  {
    "ts": null,
    "headline": "This S&P 500 Stock Soared While the Market Plunged. Is It Still a Buy Now?",
    "summary": "Roughly four out of five S&P 500 (SNPINDEX: ^GSPC) stocks are in negative territory in 2025.  Most of those stocks weren't immune to the meltdown that occurred in recent days following President Trump's \"Liberation Day\" announcement of steep reciprocal tariffs.  At least one S&P 500 stock soared as the market plunged.",
    "url": "https://finnhub.io/api/news?id=fe1372fce0b70b9cb669784036c23e8e1099e822e61ea913ecffce629d3ccf15",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744275060,
      "headline": "This S&P 500 Stock Soared While the Market Plunged. Is It Still a Buy Now?",
      "id": 133844034,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "UNH",
      "source": "Yahoo",
      "summary": "Roughly four out of five S&P 500 (SNPINDEX: ^GSPC) stocks are in negative territory in 2025.  Most of those stocks weren't immune to the meltdown that occurred in recent days following President Trump's \"Liberation Day\" announcement of steep reciprocal tariffs.  At least one S&P 500 stock soared as the market plunged.",
      "url": "https://finnhub.io/api/news?id=fe1372fce0b70b9cb669784036c23e8e1099e822e61ea913ecffce629d3ccf15"
    }
  },
  {
    "ts": null,
    "headline": "ClearBridge Growth Strategy Q1 2025 Commentary",
    "summary": "The ClearBridge Growth Strategy underperformed its Russell Midcap Growth Index benchmark in the first quarter. Read more here.",
    "url": "https://finnhub.io/api/news?id=da2e1e3d9495f6befc4628d9a57d186fa9b60f0850b60f20f64dc6cc8809362a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744273140,
      "headline": "ClearBridge Growth Strategy Q1 2025 Commentary",
      "id": 133843128,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1359132436/image_1359132436.jpg?io=getty-c-w1536",
      "related": "UNH",
      "source": "SeekingAlpha",
      "summary": "The ClearBridge Growth Strategy underperformed its Russell Midcap Growth Index benchmark in the first quarter. Read more here.",
      "url": "https://finnhub.io/api/news?id=da2e1e3d9495f6befc4628d9a57d186fa9b60f0850b60f20f64dc6cc8809362a"
    }
  },
  {
    "ts": null,
    "headline": "UnitedHealth Group (NYSE:UNH) Climbs 20% In One Month",
    "summary": "UnitedHealth Group (NYSE:UNH) saw its share price rise by 20% over the last month, a significant move against the backdrop of the broader market's recent volatility. While no specific events related directly to UnitedHealth could be isolated as a catalyst, the market's overall fluctuations highlighted by the recent 3,000-point jump in the Dow Jones and a 12% increase in the Nasdaq may have provided a supportive environment. Trump's temporary pause on tariffs likely pacified investor concerns,...",
    "url": "https://finnhub.io/api/news?id=92e11beffc7a736c7442ce89e256e2603599bcd1776c43b26126968564177d22",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1744243272,
      "headline": "UnitedHealth Group (NYSE:UNH) Climbs 20% In One Month",
      "id": 133841316,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "UNH",
      "source": "Yahoo",
      "summary": "UnitedHealth Group (NYSE:UNH) saw its share price rise by 20% over the last month, a significant move against the backdrop of the broader market's recent volatility. While no specific events related directly to UnitedHealth could be isolated as a catalyst, the market's overall fluctuations highlighted by the recent 3,000-point jump in the Dow Jones and a 12% increase in the Nasdaq may have provided a supportive environment. Trump's temporary pause on tariffs likely pacified investor concerns,...",
      "url": "https://finnhub.io/api/news?id=92e11beffc7a736c7442ce89e256e2603599bcd1776c43b26126968564177d22"
    }
  }
]